Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models

Table 9 Comparison of models to predict outcome of liver transplant patients

Variable	c-statistic (95%CI)
	For recurrence	For death
Number of elevated biomarkers	0.66 (0.57-0.75)	0.66 (0.59-0.73)
BALAD Score (per increase of 1)	0.64 (0.55-0.73)	0.65 (0.58-0.73)
BALAD-2 Score (per increase of 1)	0.61 (0.52-0.70)	0.61 (0.54-0.68)
Within Milan criteria at diagnosis	0.56 (0.49-0.62)	0.58 (0.54-0.63)
Within UCSF criteria at diagnosis	0.55 (0.49-0.60)	0.59 (0.55-0.63)
Within Milan criteria at transplant	0.53 (0.46-0.59)	0.52 (0.47-0.57)
Within UCSF criteria at transplant	0.53 (0.48-0.58)	0.50 (0.47-0.54)
z-GALAD	0.63 (0.53-0.72)	0.64 (0.56-0.72)
GALAD score	0.63 (0.53-0.72)	0.64 (0.56-0.72)
AFP model (explant model)	0.59 (0.51-0.67)	0.58 (0.51-0.65)